Short-term outcomes following treatment of recalcitrant cystoid macular edema secondary to radiation maculopathy using intravitreal brolucizumab

Giulia Corradetti; Federico Corvi; Alexander Juhn; SriniVas R. Sadda

American Journal of Ophthalmology Case Reports (Dec 2020)

Short-term outcomes following treatment of recalcitrant cystoid macular edema secondary to radiation maculopathy using intravitreal brolucizumab

Giulia Corradetti,
Federico Corvi,
Alexander Juhn,
SriniVas R. Sadda

Affiliations

Giulia Corradetti: Doheny Eye Institute, University of California Los Angeles (UCLA), 1355 San Pablo Street, Los Angeles, CA, United States; Retina Disorders and Ophthalmic Genetics, Stein Eye Institute, University of California-Los Angeles, 100 Stein Plaza Dr, Los Angeles, CA, United States
Federico Corvi: Doheny Eye Institute, University of California Los Angeles (UCLA), 1355 San Pablo Street, Los Angeles, CA, United States; Eye Clinic, Department of Biomedical and Clinical Science “Luigi Sacco”, via Giovanni Battisti Grassi, 71, Sacco Hospital, University of Milan, Milan, Italy
Alexander Juhn: Doheny Eye Institute, University of California Los Angeles (UCLA), 1355 San Pablo Street, Los Angeles, CA, United States; Retina Disorders and Ophthalmic Genetics, Stein Eye Institute, University of California-Los Angeles, 100 Stein Plaza Dr, Los Angeles, CA, United States; Department of Ophthalmology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA, United States
SriniVas R. Sadda: Doheny Eye Institute, University of California Los Angeles (UCLA), 1355 San Pablo Street, Los Angeles, CA, United States; Retina Disorders and Ophthalmic Genetics, Stein Eye Institute, University of California-Los Angeles, 100 Stein Plaza Dr, Los Angeles, CA, United States; Department of Ophthalmology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA, United States; Corresponding author. 1355 San Pablo Street, Suite 211, Los Angeles, CA, 90033, United States.

Journal volume & issue: Vol. 20
p. 100981

Abstract

Read online

Purpose: To assess the efficacy of intravitreal brolucizumab (Beovu®, Novartis Pharmaceuticals) in a case of recalcitrant cystoid macular edema associated with radiation maculopathy secondary to retinoblastoma which was suboptimally responsive to other intravitreal anti-vascular endothelial growth factor (VEGF) therapies. Observations: A 42-year old patient with a history of radiation maculopathy complicated by cystoid macular edema after chemoreduction treatment and radiation therapy for retinoblastoma was treated with intravitreal brolucizumab. Best-corrected visual acuity and central macular thickness assessed by optical coherence tomography were used to assess the clinical outcomes. The treated eye was also assessed for evidence of intraocular inflammation following injection. Cystoid macular edema showed marked reduction and near resolution two weeks after injection and improvement in best-corrected visual acuity which was maintained for 2 months of follow-up. No ocular inflammatory reactions or other adverse events were reported. Conclusions and Importance: This case of radiation maculopathy refractory to other intravitreal anti-VEGF treatments showed good treatment response to brolucizumab therapy.

Published in American Journal of Ophthalmology Case Reports

ISSN: 2451-9936 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Ophthalmology
Website: http://www.journals.elsevier.com/american-journal-of-ophthalmology-case-reports/

About the journal

Abstract

Keywords